Similar articles for PMID: 27212123

Year	Number of Results
2013	3
2014	10
2015	15
2016	27
2017	32
2018	21
2019	24
2020	21
2021	18
2022	17
2023	8
2024	0

1

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.

Zhang W, Wu TY, Chen Q, Shi XL, Xiao GA, Zhao L, Xu CL, Zhou T, Sun YH. Zhang W, et al. Asian J Androl. 2017 Mar-Apr;19(2):196-202. doi: 10.4103/1008-682X.178483. Asian J Androl. 2017. PMID: 27212123 Free PMC article. Review.

2

Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.

Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Miyake H, et al. Urol Oncol. 2017 Jun;35(6):432-437. doi: 10.1016/j.urolonc.2017.01.006. Epub 2017 Feb 8. Urol Oncol. 2017. PMID: 28188090

3

Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.

Chang LW, Hung SC, Wang SS, Li JR, Yang CK, Chen CS, Ho HC, Cheng CL, Ou YC, Chiu KY. Chang LW, et al. Anticancer Res. 2019 Jul;39(7):3901-3908. doi: 10.21873/anticanres.13541. Anticancer Res. 2019. PMID: 31262919

4

Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.

Miyake H, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Med Oncol. 2017 Nov 21;34(12):200. doi: 10.1007/s12032-017-1060-9. Med Oncol. 2017. PMID: 29164346

5

Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.

Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A. Miyake H, et al. Clin Genitourin Cancer. 2018 Jun;16(3):219-225. doi: 10.1016/j.clgc.2017.11.007. Epub 2017 Dec 6. Clin Genitourin Cancer. 2018. PMID: 29274813

6

Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. Smith MR, et al. Eur Urol. 2017 Jul;72(1):10-13. doi: 10.1016/j.eururo.2017.03.007. Epub 2017 Mar 15. Eur Urol. 2017. PMID: 28314611

7

Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Miyake H, et al. Clin Genitourin Cancer. 2017 Aug;15(4):e591-e597. doi: 10.1016/j.clgc.2016.12.015. Epub 2016 Dec 22. Clin Genitourin Cancer. 2017. PMID: 28063845

8

Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis.

Cassinello J, Domínguez-Lubillo T, Gómez-Barrera M, Hernando T, Parra R, Asensio I, Casado MA, Moreno P. Cassinello J, et al. Cancer Treat Rev. 2021 Feb;93:102152. doi: 10.1016/j.ctrv.2020.102152. Epub 2021 Jan 11. Cancer Treat Rev. 2021. PMID: 33486302

9

Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?

Pereira-Salgado A, Kwan EM, Tran B, Gibbs P, De Bono J, IJzerman M. Pereira-Salgado A, et al. Eur Urol Focus. 2021 Jul;7(4):752-763. doi: 10.1016/j.euf.2020.03.003. Epub 2020 Apr 6. Eur Urol Focus. 2021. PMID: 32273196 Review.

10

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.

Yamada Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S. Yamada Y, et al. BMC Res Notes. 2016 Oct 18;9(1):471. doi: 10.1186/s13104-016-2279-9. BMC Res Notes. 2016. PMID: 27756383 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

154 results

Results by year